AXL Kinase Inhibitor - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “AXL Kinase Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in AXL Kinase Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
AXL Kinase Inhibitor: Overview
Axl receptor tyrosine Kinase is a member of the tyrosine?protein Kinase receptor Tyro3, Axl and proto?oncogene tyrosine?protein Kinase Mer family of receptor tyrosine Kinases. AXL is a member of a complex signaling network that is involved in the control of cell proliferation and differentiation. AXL is widely expressed in healthy tissues, where it plays a variety of roles, including clearing apoptotic material, regulating cell survival, maintaining vascular integrity, and hematopoiesis. AXL has emerged as a novel biomarker due to its role in biological processes and tumorigenesis. Because of the pleiotropic role of AXL in tumor pathophysiology and drug resistance, AXL represents a promising therapeutic target in the management of cancer. AXL inhibitors have been shown to potentiate tumor cell apoptosis and suppress migration and invasion. Targeting AXL enhances the therapeutic efficacy of chemotherapy and other small-molecule inhibitors, such as VEGF, EGFR, PI3K, PARP, and HER2 inhibitors.
Report Highlights
This segment of the AXL Kinase Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
AXL Kinase Inhibitor Emerging Drugs
Further product details are provided in the report……..
AXL Kinase Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different AXL Kinase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
AXL Kinase Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses AXL Kinase Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging AXL Kinase Inhibitor drugs.
AXL Kinase Inhibitor Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “AXL Kinase Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in AXL Kinase Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
AXL Kinase Inhibitor: Overview
Axl receptor tyrosine Kinase is a member of the tyrosine?protein Kinase receptor Tyro3, Axl and proto?oncogene tyrosine?protein Kinase Mer family of receptor tyrosine Kinases. AXL is a member of a complex signaling network that is involved in the control of cell proliferation and differentiation. AXL is widely expressed in healthy tissues, where it plays a variety of roles, including clearing apoptotic material, regulating cell survival, maintaining vascular integrity, and hematopoiesis. AXL has emerged as a novel biomarker due to its role in biological processes and tumorigenesis. Because of the pleiotropic role of AXL in tumor pathophysiology and drug resistance, AXL represents a promising therapeutic target in the management of cancer. AXL inhibitors have been shown to potentiate tumor cell apoptosis and suppress migration and invasion. Targeting AXL enhances the therapeutic efficacy of chemotherapy and other small-molecule inhibitors, such as VEGF, EGFR, PI3K, PARP, and HER2 inhibitors.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence AXL Kinase Inhibitor R&D. The therapies under development are focused on novel approaches for AXL Kinase Inhibitor.
This segment of the AXL Kinase Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
AXL Kinase Inhibitor Emerging Drugs
- Bemcentinib: BerGenBio / Rigel Pharmaceuticals
- Sitravatinib: Mirati Therapeutics
Further product details are provided in the report……..
AXL Kinase Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different AXL Kinase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on AXL Kinase Inhibitor
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
AXL Kinase Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses AXL Kinase Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging AXL Kinase Inhibitor drugs.
AXL Kinase Inhibitor Report Insights
- AXL Kinase Inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing AXL Kinase Inhibitor drugs?
- How many AXL Kinase Inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for AXL Kinase Inhibitor?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the AXL Kinase Inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for AXL Kinase Inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
- BerGenBio
- Rigel Pharmaceuticals
- Mirati Therapeutics
- Ipsen
- SignalChem Lifesciences
- Arcus Biosciences
- Symphogen
- Qurient Co
- Daiichi Sankyo Company
- Aravive
- Exelixis
- Bemcentinib
- Sitravatinib
- Cabozantinib
- Research programme: TAM inhibitors
- Research programme: AXL receptor tyrosine kinase inhibitors
- Sym 028
- Q-702
- AB 329
- Aravive S6
- XL092
Introduction
Executive Summary
AXL Kinase Inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
AXL Kinase Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
AXL Kinase Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
AXL Kinase Inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Sitravatinib: Mirati Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Bemcentinib: BerGenBio/Rigel Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
AB 329: Daiichi Sankyo Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Q-702: Qurient Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
AXL Kinase Inhibitor Key Companies
AXL Kinase Inhibitor Key Products
AXL Kinase Inhibitor- Unmet Needs
AXL Kinase Inhibitor- Market Drivers and Barriers
AXL Kinase Inhibitor- Future Perspectives and Conclusion
AXL Kinase Inhibitor Analyst Views
AXL Kinase Inhibitor Key Companies
Appendix
Executive Summary
AXL Kinase Inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
AXL Kinase Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
AXL Kinase Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
AXL Kinase Inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Sitravatinib: Mirati Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Bemcentinib: BerGenBio/Rigel Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
AB 329: Daiichi Sankyo Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Q-702: Qurient Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
AXL Kinase Inhibitor Key Companies
AXL Kinase Inhibitor Key Products
AXL Kinase Inhibitor- Unmet Needs
AXL Kinase Inhibitor- Market Drivers and Barriers
AXL Kinase Inhibitor- Future Perspectives and Conclusion
AXL Kinase Inhibitor Analyst Views
AXL Kinase Inhibitor Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for AXL Kinase Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for AXL Kinase Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for AXL Kinase Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for AXL Kinase Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products